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Studies of the Escherichia, Neisseria, Thermotoga, and Mycobacteria clustered regularly interspaced short
palindromic repeat (CRISPR) subtypes have resulted in a model whereby CRISPRs function as a defense
system against bacteriophage infection and conjugative plasmid transfer. In contrast, we previously showed
that the Yersinia-subtype CRISPR region of Pseudomonas aeruginosa strain UCBPP-PA14 plays no detectable
role in viral immunity but instead is required for bacteriophage DMS3-dependent inhibition of biofilm
formation by P. aeruginosa. The goal of this study is to define the components of the Yersinia-subtype CRISPR
region required to mediate this bacteriophage-host interaction. We show that the Yersinia-subtype-specific
CRISPR-associated (Cas) proteins Csy4 and Csy2 are essential for small CRISPR RNA (crRNA) production
in vivo, while the Csy1 and Csy3 proteins are not absolutely required for production of these small RNAs.
Further, we present evidence that the core Cas protein Cas3 functions downstream of small crRNA production
and that this protein requires functional HD (predicted phosphohydrolase) and DEXD/H (predicted helicase)
domains to suppress biofilm formation in DMS3 lysogens. We also determined that only spacer 1, which is not
identical to any region of the DMS3 genome, mediates the CRISPR-dependent loss of biofilm formation. Our
evidence suggests that gene 42 of phage DMS3 (DMS3-42) is targeted by CRISPR2 spacer 1 and that this
targeting tolerates multiple point mutations between the spacer and DMS3-42 target sequence. This work
demonstrates how the interaction between P. aeruginosa strain UCBPP-PA14 and bacteriophage DMS3 can be
used to further our understanding of the diverse roles of CRISPR system function in bacteria.
core Cas proteins encoded by CRISPR regions raises the question of whether CRISPRs may play roles in microbial biology
other than resistance to invasion by foreign genetic elements.
Indeed, there is a growing body of evidence that not all
CRISPR regions are capable of conferring resistance to foreign DNA elements (5, 8, 19, 24, 27).
We previously reported that the Yersinia-subtype CRISPR
of Pseudomonas aeruginosa strain UCBPP-PA14 (PA14) does
not confer any detectable resistance to bacteriophage infection
(5) but is instead required for altering group behaviors when
this microbe is lysogenized by bacteriophage DMS3 (27). In
this previous work, we provided evidence that the cause of
biofilm inhibition was not the alteration of growth or the initiation of the lytic cycle by bacteriophage DMS3 (27). Here, we
characterize the requirement for components of the CRISPR
region in bacteriophage DMS3-dependent inhibition of biofilm
formation by P. aeruginosa PA14 and assess the role of the Cas
proteins in this bacteriophage-host interaction. Furthermore,
we present the first example of a non-identity-mediated interaction between a spacer and bacteriophage that results in a
biologically meaningful output. Finally, this is the first report to
characterize the target sequence required for a spacer to interact with a chromosomally integrated bacteriophage. In summary, this work dissects the in vivo contributions of each component of the prevalent Yersinia-subtype CRISPR region by
using a bacterium-bacteriophage interaction that impacts biofilm formation as the functional readout.

Clustered regularly interspaced short palindromic repeats
(CRISPRs) are important for the interaction of bacteria with
foreign genetic material such as bacteriophage and conjugative
plasmids (1, 16). CRISPRs are transcribed as long preCRISPR RNAs that are processed into small CRISPR RNAs
(crRNAs) by protein products of CRISPR-associated (cas)
genes (3, 11). These small crRNAs in association with select
Cas proteins have been shown to mediate resistance to bacteriophage infection and plasmid inheritance in bacteria, an observation that has led to the CRISPR systems being labeled as
bacterial adaptive immune systems (1, 16).
A CRISPR region is comprised of a locus encoding the
precursor CRISPR RNA as well as a suite of cas genes. There
have been 8 CRISPR region subtypes identified to date,
namely, Escherichia, Yersinia, Neisseria, Desulfovibrio, Thermotoga, Haloarcula, Aeropyrum, and Mycobacteria, each of which
has a distinctive CRISPR repeat sequence and at least 2 cas
genes found only in that subtype (abbreviated csx, where x
denotes the first letter of the subtype) (23). The ubiquitous cas
gene, cas1, is the only CRISPR-associated gene found in all
subtypes, and it is hypothesized to function in the acquisition of
new sequences into CRISPRs (25). There are additional cas
genes that are shared between some subtypes, termed “core”
cas genes (23). Together, the diversity of subtype-specific and
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MATERIALS AND METHODS
Strains and media. Strains, plasmids, and primers used in this study are listed
in Table S1 in the supplemental material. The P. aeruginosa strain UCBPP-PA14
(abbreviated P. aeruginosa PA14) was used in this study. P. aeruginosa and
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Escherichia coli strains were routinely cultured in lysogeny broth (LB) at 37°C.
The minimal medium used was M63 supplemented with MgSO4 (1 mM) and
arginine (0.4%). Growth media were supplemented with antibiotics at the following concentrations: ampicillin (Ap), 150 g ml⫺1 (E. coli); gentamicin (Gm),
10 g ml⫺1 (E. coli) and 50 g ml⫺1 (P. aeruginosa); and carbenicillin, 50 g
ml⫺1 (E. coli) and 500 g ml⫺1 (P. aeruginosa).
Generating lysogens of P. aeruginosa. Bacteriophage DMS3 was purified from
a lysogenized P. aeruginosa PA14 strain (SMC3884) by passage of an LB-grown
culture through a 0.22-m filter (Millipore, Billerica, MA). Lysogenic strains
were created by incubation of 10 l of purified DMS3 with 10 l of wild-type
(WT) P. aeruginosa PA14 (or mutant) in 500 l of LB for 2 h at 37°C with
shaking. Following incubation, cultures were struck to single colonies on LB agar
plates and incubated at 37°C overnight. Single colonies were picked and tested
for phage production using the plaque assay described below.
Plaque assay. DMS3 bacteriophage production was determined using a plaque
assay, as described by Budzik et al. (4). Briefly, 100 l of P. aeruginosa PA14 was
added to 3 ml of molten top agar (0.8%) and poured over a prewarmed LB agar
plate. Strains to be tested for DMS3 production were grown overnight at 37°C in
LB and filter sterilized using a 0.22-m filter. After solidification of top agar
lawns, 5-l portions of serially diluted filter-sterilized control and test lysates
were spotted onto the top agar lawn and incubated at 37°C overnight. Plaques
were counted and expressed as numbers of PFU/ml.
Static biofilm assay and quantification. Biofilm formation at 24 h on polyvinyl
chloride (PVC) plastic was assayed essentially as previously described by
O’Toole and Kolter (17), except that M63 was supplemented with 0.4% arginine
and 1 mM MgSO4. Quantification of biofilm formation was performed as follows:
crystal violet (CV) stain was solubilized from PVC-attached cells by using 150 l
of acetic acid (30% in water) per microtiter dish well. After incubation at room
temperature for ⬃10 min, 100 l of the acetic acid-solubilized CV was transferred into a fresh, optically clear, flat-bottom microtiter plate and the absorbance measured at 550 nm on a Spectra Max M2 microplate reader (Molecular
Devices, Sunnyvale, CA).
Strain construction. The construction of the strains used in this study is
detailed below.
(i) In-frame deletion mutants. In-frame deletions of the csy3, csy2, csy1, cas3,
and cas1 genes and DMS3 gene 42 (designated DMS3-42) were created using
constructs pMQ30-⌬csy3, pMQ30-⌬csy2, pMQ30-⌬csy1, pMQ30-⌬cas1, pMQ30⌬cas3, and pMQ30-⌬DMS3-42. These constructs were created utilizing the Saccharomyces cerevisiae recombineering technique described by Shanks et al. (21).
Constructs were electroporated into E. coli and analyzed by colony PCR or
sequencing. Plasmids were propagated in E. coli S17 and conjugated into P.
aeruginosa PA14 as previously reported (13). Exconjugants containing an inserted plasmid were selected on gentamicin before counterselection on 5%
sucrose. All mutations were confirmed via PCR amplification and sequencing of
the mutated region.
(ii) Allelic replacement complementation of ⌬cas3 mutation. Allelic replacement complementation of the ⌬cas3 mutation was performed using constructs
pMQ30-cas3 KON (“KON” stands for “knock-on” and distinguishes plasmids
used to introduce mutations onto the chromosome from complementation
plasmids with similar names), pMQ30-cas3(D124A) KON, and pMQ30cas3(D576A) KON. Constructs and strains were created in a manner similar to
in-frame deletions, except that WT or mutant cas3 was located between the
regions of homology.
(iii) Allelic replacement complementation of ⌬DMS3-42 mutation. Allelic
replacement complementation of the ⌬DMS3-42 mutation was performed similarly to that of the ⌬cas3 mutation, except constructs pMQ30-DMS3-42 KON,
pMQ30-DMS3-42(T2G) KON, pMQ30-DMS3-42(C234T) KON, pMQ30DMS3-42(G235T) KON, pMQ30-DMS3-42(C238T) KON, pMQ30-DMS342(C238G) KON, pMQ30-DMS3-42(C243T) KON, pMQ30-DMS3-42(C246T)
KON, pMQ30-DMS3-42(C249T) KON, pMQ30-DMS3-42(C252T) KON,
pMQ30-DMS3-42(T254C) KON, pMQ30-DMS3-42(C256A C258A) KON,
pMQ30-DMS3-42(G261T) KON, pMQ30-DMS3-42(A262T) KON, pMQ30DMS3-42(C663T) KON, and pMQ30-DMS3-42(G681T) KON were utilized.
Constructs and strains were created in a manner similar to in-frame deletions,
except that WT or mutant DMS3-42 was located between the regions of homology. The loss of DMS3-42 gene function resulted in a complete loss of phage
DMS3 production, and the successful complementation of ⌬DMS3-42 mutants
was assayed by the renewed production of DMS3 bacteriophage, as measured by
plaque assay.
(iv) Allelic replacement complementation of the ⌬CRISPR2 mutation. Allelic
replacement complementation of the ⌬CRISPR2 mutation was performed using constructs pMQ30-CRISPR2 KON, pMQ30-⌬spacer20 KON, pMQ30⌬spacer17 KON, pMQ30-⌬spacers7-21 KON, pMQ30-⌬spacers2-21 KON,

J. BACTERIOL.
pMQ30-⌬spacers1-21 KON, pMQ30-⌬spacers1-2 KON, pMQ30-spacers1 SalI
KON, and pMQ30-spacer 1 BamHI KON. S. cerevisiae recombineering techniques were also used to make these constructs. Primers CRISPR2 KON for and
CRISPR2 KON rev were used in conjunction with mutation-specific forward and
reverse primers, which annealed within the CRISPR region (see Fig. S1 in the
supplemental material). The only exception to this was pMQ30-CRISPR2 KON,
which utilized only CRISPR2 KON for and CRISPR2 KON rev primer set (see
Fig. S1). Internal primers contained sequence identity to the spacer and repeat
to the left or right of the desired mutation, allowing for specificity of amplification. Internal spacers for all deletion constructs contained the full sequence of P.
aeruginosa strain PA2192 CRISPR1 spacer 8 (CGC ATT GCC AGG ATC AGC
ACG TCG ACC ATC TT) at one end of the primer, while point mutation
primers harbored the desired point mutations within the spacer 1 sequence. The
PA2192 spacer contained a SalI restriction site, simplifying the identification of
properly recombineered plasmids. When these primers were utilized in PCR, we
obtained 2 products, each with sequence identity either upstream or downstream
of CRISPR2 (see Fig. S1). These products recombined with each other at the
PA2192 spacer sequence and at the vector pMQ30, creating the desired
CRISPR2 allelic replacement construct. A diagram of the PCR products generated for representative CRISPR2 mutations is shown in Fig. S1.
(v) Extrachromosomal complementation constructs. Extrachromosomal complementation constructs pMQ70-csy4His, pMQ70-csy4His(H29A), pMQ70csy4His(H29K), pMQ70-E. coli csy4His, pMQ70-E. coli csy4His(H29A), pMQ70csy3, pMQ70-csy2, pMQ70-csy1, pMQ70-cas3, pMQ70-cas3(D124A), and
pMQ70-cas3(D576A) were created using recombineering as previously described (21). The pMQ70 derivative plasmid pDPM73 (14) was utilized as the
vector and digested with XhoI and EcoRI (New England BioLabs, Beverly, MA).
Forward and reverse primers (see Table S1 in the supplemental material) were
used to PCR amplify wild-type and mutant genes, which were then utilized in
yeast recombination reactions to form complementation constructs. Plasmids
were purified from yeast cells, electroporated into E. coli Top10 cells (Invitrogen,
Carlsbad, CA), prepared using the Qiagen spin miniprep kit (Valencia, CA), and
electroporated into P. aeruginosa PA14 strains as previously described (6). Plasmid selection was maintained with 50 g ml⫺1 carbenicillin both on LB plates
and in LB liquid cultures.
Northern blot analysis. Northern blot assays were performed to determine the
ability of various deletion and point mutations to process the native full-length
CRISPR transcript into small crRNAs in vivo. Cultures grown overnight in LB
medium either supplemented with carbenicillin and arabinose (harboring complementation constructs) or not supplemented (deletion or chromosomal allelic
replacement strains) were pelleted and resuspended in 100 l of TE (TrisEDTA) buffer containing 400 g/ml lysozyme for 3 to 5 min at room temperature. Following lysozyme-mediated cell lysis, total RNA was purified using a
mirVana microRNA (miRNA) isolation kit (Ambion, Austin, TX) by essentially
following the manufacturer’s instructions for total RNA extraction. Two 10%
TBE (Tris-borate-EDTA)-urea polyacrylamide gels (Bio-Rad, Hercules, CA)
were loaded with 10 g of total RNA per sample lane and resolved at 50 V.
Following electrophoresis, one gel was transferred to a nylon membrane
(Thermo Scientific, Rockford, IL) for Northern analysis while the other was
stained with ethidium bromide and photographed under UV light to serve as an
additional loading control. Primers Northern Marker/probe For (TGG ATT
CAT GTA TCA GGC ATC GTA CTC GGC AAT TTC TTA GCT GCC TAC
ACG GC) and Northern Marker/probe Rev2 (ATC CTC GAA CAG CCC GGG
TTC GGT CGC CTC CAG TTC ACT GC) were utilized in PCRs to synthesize
a probe comprising the last 4 spacers and 3 repeats of P. aeruginosa PA14
CRISPR2. The random primed DNA labeling kit (Roche, Indianapolis, IN) and
[␣-32P]dCTP (3,000 Ci mmol⫺1; PerkinElmer, Waltham, MA) were utilized
according to the manufacturer’s specifications to radioactively label the probe.
mirVana-suggested small RNA (sRNA) prehybridization, hybridization, and
wash solutions were utilized at 65°C, 37°C, and 37°C respectively. Under these
hybridization conditions, this probe hybridized with the conserved repeat region
of all CRISPR-derived small crRNAs regardless of spacer sequence. Following
the third 15-min wash, membranes were covered with plastic wrap and exposed
to a storage phosphor screen (GE Healthcare, Piscataway, NJ) overnight. After
exposure, phosphor screens were read on a Storm 860 (Molecular Devices,
Sunnyvale, CA) and processed using Image Quant software v5.2 (Molecular
Devices, Sunnyvale, CA).
Detection of Cas3 and penta-His-tagged Cas proteins. The following section
describes the methods used in the Western blot studies.
(i) Penta-His-tagged-protein detection. C-terminal penta-His epitope tagfused Csy4 and E. coli Csy4, Csy2, and Csy1 proteins were expressed under an
arabinose-inducible pBad promoter. To detect the level of His-tagged proteins,
cultures were grown with shaking overnight in 5 ml of LB medium containing 50
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FIG. 1. Deletion and complementation analysis of P. aeruginosa PA14 CRISPR region. (A) Chromosomal organization of the CRISPR
genomic region, including the two CRISPRs and CRISPR-associated (cas) genes. CRISPRs are shown as black boxes, Yersinia-subtype cas
genes are depicted as dark gray arrows, and core cas genes found in multiple CRISPR subtypes are diagrammed as light gray arrows.
(B) Biofilm phenotypes of wild-type and deletion mutants in the absence of bacteriophage DMS3 (nonlysogens). A representative image of
the biofilm formed by each strain is shown above the quantification of results for 8 independent wells. The ⌬CRISPR1 strain has only
CRISPR1 deleted, the ⌬CRISPR2 strain has only CRISPR2 deleted, and the ⌬CR strain has both CRISPRs and the cas genes they flank
deleted. (C) Biofilm phenotypes of bacteriophage DMS3-infected (DMS3 lysogens) wild-type and mutant strains. A representative image of
the biofilm formed by each strain is shown above the quantification of results for 8 independent wells. An “L” following a strain designation,
in this panel and panel D, indicates a strain lysogenized with DMS3. (D) Complementation analysis of the csy4, csy3, csy2, csy1, and cas3
mutants in DMS3 lysogens. A representative image of the biofilm formed by each strain is shown above the quantification of results for 8
independent wells.

g ml⫺1 carbenicillin and 0.2% arabinose. Overnight cultures (100 l) were
boiled in sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDSPAGE) loading buffer and resolved using SDS-PAGE. His-tagged Csy4 was
detected via Western blot analysis using penta-His antibody (Qiagen, Valencia,
CA), per the manufacturer’s instructions.
(ii) Cas3 level determination. Cas3 levels were determined after overnight
growth in M63 minimal medium supplemented with 0.4% arginine and 1 mM
MgSO4. M63 medium was utilized because less background was observed after
growth in minimal medium than after that in LB medium. Similar to Western
blot analyses detecting the His tag epitope, 100-l portions of overnight cultures
were boiled in sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDSPAGE) loading buffer and resolved using SDS-PAGE. Cas3 proteins were detected via Western blot analysis using polyclonal rabbit antibodies against Cas3
(Josman Inc., Napa, CA).

RESULTS
P. aeruginosa cas genes involved in bacteriophage DMS3mediated biofilm inhibition. The laboratory strain P. aeruginosa PA14 harbors two repeat-rich CRISPR loci flanking a
series of 6 cas genes. Four of these cas genes are unique to
Yersinia-subtype CRISPR regions, while two are core cas
genes found in multiple subtypes (Fig. 1A). We previously
reported that infection of P. aeruginosa PA14 with lysogenic
bacteriophage DMS3 results in disruption of biofilm formation and that the biofilm phenotype is restored in lysogenic
strains with gene disruptions in either CRISPR2, csy1, csy2,
csy3, csy4, or cas3 (27). To further dissect this bacteriophage-host interaction and to determine the contribution of
each component of the Yersinia-subtype CRISPR region to

DMS3-mediated biofilm inhibition, we systematically deleted each of the components of the Csy-type CRISPR
system.
To clearly establish the role of each cas gene in this biofilm
phenotype, we made in-frame deletions of each cas gene, complemented these deletions, and determined their biofilm phenotypes in nonlysogenized and lysogenized strain backgrounds
(Fig. 1B to D). We also deleted each CRISPR or the entire
CRISPR region, including both CRISPRs and all cas genes,
and performed a similar analysis. Deletion of either CRISPR,
any cas gene, or the entire CRISPR region has no effect on
biofilm formation in the absence of bacteriophage DMS3 (i.e.,
nonlysogens) (Fig. 1B). This observation indicates that neither
the cas genes nor either CRISPR is required for biofilm formation under these conditions.
When these mutants are lysogenized by bacteriophage
DMS3, however, a biofilm-defective phenotype can be observed in some strains (Fig. 1C). As expected, the wild-type P.
aeruginosa PA14 is unable to form a biofilm when lysogenized
by DMS3 (27). Similarly, when lysogenized, the ⌬CRISPR1
and ⌬cas1 mutant strains are also unable to form a biofilm,
indicating that these loci do not contribute to the DMS3dependent loss of biofilm formation. These findings are consistent with our previous study indicating that CRISPR1 and
cas1 are dispensable for the DMS3-dependent biofilm phenotype (27). In contrast, when lysogenized by DMS3, the
⌬CRISPR2, ⌬csy1, ⌬csy2, ⌬csy3, ⌬csy4, and ⌬cas3 mutant
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FIG. 2. Characterization of small crRNA production by CRISPR region mutants. (A) Diagram showing CRISPR DNA transcribed into a long
CRISPR transcript, which is processed into mature crRNAs by Cas proteins. The portion of CRISPR2 utilized as the probe for Northern blot
analysis is denoted by a dashed line. Unique spacer sequences are shown as gray boxes, while repeat sequences are represented by black lines.
(B) Detection of in vivo small crRNA production by WT, ⌬CRISPR1, ⌬CRISPR2, and ⌬CRISPR region nonlysogens and lysogens by using
Northern blot analysis. Also shown is the 5S rRNA band for each of the corresponding RNA preparations used in the Northern blot analysis.
(C) Shown is a representative Northern blot (top) of crRNA production by each cas mutant in the absence of DMS3. Also shown is the 5S rRNA
band for each of the corresponding RNA preparations used in the Northern blot analysis. (D) Shown is a representative Northern blot (top) of
crRNA production by cas mutants in the presence of DMS3 (lysogens). Also shown is the 5S rRNA band for each of the corresponding RNA
preparations used in the Northern blot analysis. (E) Quantification of representative data shown in panel D. Shown is an average calculated from
three replicate experiments. The bars indicate standard deviation. *, Significantly different from the WT, P ⬍ 0.05. An “L” following the genotype
designation indicates a strain lysogenized with DMS3.

strains, as well as the strain lacking the entire region (⌬CR
strain), regain the ability to form a biofilm (Fig. 1C, compare to
the WT lysogen).
Each biofilm-positive cas mutant phenotype could be completely or partially complemented with plasmids expressing
penta-His-tagged proteins (Fig. 1D). We noticed poor complementation of the ⌬cas3 mutant by the plasmid-borne cas3 gene
(Fig. 1D, far right); however, as shown below, we could complement the cas3 mutation by replacing the mutant allele on
the chromosome with the WT gene. A mutation in CRISPR2
could also be complemented by the reintroduction of the
CRISPR at the native locus (see below).
Together, these data confirm and extend our previous findings (27) and allow us to address the contribution of each
component of the CRISPR region to the inhibition of biofilm
formation in the DMS3-lysogenized strains.
Requirement for cas gene products in small crRNA production in vivo. Functional CRISPR regions are transcribed as a
large RNA that is subsequently processed into mature small
crRNAs by selected Cas proteins (Fig. 2A) (3, 10). To determine which cas gene products are involved in processing the
CRISPR transcripts into small crRNAs in vivo, we utilized
Northern blot analysis with a probe constituting the 4 spacers
and 3 repeats closest to the cas1 gene (Fig. 2A, dashed black
bar).
The Northern assay probe, which contains both repeat and
spacer sequences, cross-hybridizes specifically with the conserved repeat sequence retained in small crRNAs derived from

the Yersinia-subtype CRISPR region (regardless of spacer content) as previously observed (5) (Fig. 2B, compare WT and
⌬CR lanes). Furthermore, we can detect small crRNAs derived from both CRISPR1 and CRISPR2, although CRISPR2derived small RNAs are either more prevalent or preferentially hybridize to this probe (Fig. 2B, compare WT,
⌬CRISPR1, and ⌬CRISPR2 lanes). Finally, comparison of
crRNA production from the lysogenized and nonlysogenized
strains indicates that levels of the crRNA do not change upon
lysogeny by DMS3 (Fig. 2B).
Analysis of crRNA production in the individual cas mutant
backgrounds revealed that only ⌬csy4 and ⌬csy2 were absolutely required for small crRNA production, although the
⌬csy3, ⌬csy1, and ⌬cas3 mutants showed significantly decreased levels of crRNAs compared to the WT (Fig. 2C to E).
While it was expected that csy4 would be required for
crRNA production, because its product has been shown to
have nuclease activity that can cleave CRISPR transcripts in
vitro (11), our data also indicate the involvement of the csy1,
csy2, and csy3 (csy1-3) and cas3 genes and their products in
crRNA production. The prediction by others (23) that Csy1 to
Csy4 (Csy1-4) may be forming a complex led us to assess the
stability of Csy4 in each cas mutant background. To this end,
we expressed penta-His-tagged Csy4 in each mutant background but observed no alteration in the stability of this nuclease in any cas or csy mutant (data not shown). These data
indicate that the products of csy1-3 and cas3 genes may be

VOL. 193, 2011

FIG. 3. In vivo analysis of P. aeruginosa and E. coli Csy4. (A) Shown
are the abilities of P. aeruginosa and E. coli plasmid-expressed WT and
Csy4 mutants to complement the intact biofilm phenotype resulting
from a ⌬csy4 mutation in the presence of bacteriophage DMS3 in
comparison to a WT lysogen. An “L” following the genotype designation indicates a strain lysogenized with DMS3. A representative image
of the biofilm formed by each strain is shown above the quantification
of results of 8 independent wells. (B) Western blot analysis of strain
indicated in panel A. The His-tagged Cys4 protein was detected using
anti-His antibody. (C) Northern blot analysis of small crRNA production by each mutant indicated in panel A. In this experiment, the three
spacers and two repeats closest to the cas1 gene of CRISPR2 of P.
aeruginosa PA14 was used as the probe (see Fig. 2A). Also shown at
the bottom of this panel is the 5S rRNA band for each of the corresponding RNA preparations used in the Northern blot analysis.

involved in CRISPR transcript processing or crRNA stabilization independent of Csy4 stability.
Catalytic residues of Csy4 are required for CRISPR transcript processing in vivo. A recent report by Doudna and
colleagues showed the Csy4 protein could process full-length
CRISPR RNA in vitro, and furthermore, they identified residues critical for this in vitro activity (11). The data presented in
Fig. 2C and D and in Fig. 3, lanes 1 and 2, show that the ⌬csy4
mutant lacks any detectable small crRNA production in vivo,
consistent with the published biochemical studies (11).
To confirm and extend these studies, we assessed the ability
of mutant Csy4 proteins, with point mutations in known catalytic sites, to mediate CRISPR processing and to impact biofilm formation in DMS3 lysogens. We constructed penta-Histagged constructs expressing the WT and mutant Csy4 proteins
and assessed the ability of the mutants to complement the
⌬csy4 mutation (Fig. 3).
Based on published biochemical data for Csy4 (11), we mutated the catalytic H29 residue of the P. aeruginosa Csy4 pro-
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tein to lysine or alanine (H29K or H29A) to assess the role of
the in vitro-documented nuclease activity on crRNA production and biofilm formation in vivo. A construct expressing
penta-His-tagged Csy4 was able to complement the ⌬csy4
mutation, resulting in ⌬csy4 lysogens regaining the ability to
disrupt biofilm formation (Fig. 3A, compare ⌬csy4 L to
⌬csy4⫹csy4 L). Mutation of P. aeruginosa Csy4 catalytic residue H29 to lysine has been shown to be active in vitro (11), and
the mutant protein retained the ability to complement biofilm
inhibition, while the in vitro catalytically dead H29A mutant
(11) was unable to complement the biofilm inhibition phenotype (Fig. 3A). Western blot analysis showed that the noncomplementing Csy4(H29A) mutant protein, while less stable
than WT Csy4, was similar in stability to the complementing
H29K mutant protein, indicating that the decreased level of
the H29A mutant protein could not explain the lack of complementation (Fig. 3B). Finally, Northern blot analysis demonstrated that the Csy4(H29K) mutant protein retained the
ability to process the CRISPR transcript into small crRNAs,
while the H29A mutants are not functional for production of
small crRNAs (Fig. 3C).
While it has been shown that a Csy4 protein from E. coli can
process a P. aeruginosa CRISPR transcript in vitro (11), to our
knowledge no study has looked at the ability of a cas protein
from one bacterial species to cross-complement another species in vivo. To this end, E. coli UTI89 csy4 was amplified and
cloned into the same vector backbone that was used for P.
aeruginosa Csy4 expression. The E. coli Csy4 protein is 49%
identical and 64% similar to Csy4 of P. aeruginosa. We found
that the E. coli Csy4 protein was able to restore biofilm inhibition to P. aeruginosa ⌬csy4 mutant lysogen (Fig. 3A). Further, the E. coli Csy4(H29A) mutant protein, like that of P.
aeruginosa, was unable to complement the biofilm inhibition
phenotype. Western and Northern blot analyses demonstrated
that the E. coli Csy4 protein is produced and functional in P.
aeruginosa and that the WT but not the H29A mutant is able
to process the P. aeruginosa CRISPR transcript into correctly
sized crRNAs in vivo (Fig. 3B).
The Yersinia-subtype CRISPR region codes for a predicted
Cas3 protein but lacks an apparent Cas2 homolog. The core
CRISPR-associated gene cas3 is found in 6 of 8 CRISPR
region subtypes and is not predicted to be complexed with Csy
proteins based on a published study (23). A recent study demonstrated that Cas3 is a single-stranded DNA nuclease and
ATP-dependent helicase in vitro (22).
We compared the sequences and predicted domains of Cas3
homologs from 3 different CRISPR region subtypes to lend
insight into Cas3 function. Alignment of Cas3 proteins from
pseudomonads and E. coli strains harboring different CRISPR
region subtypes, including P. aeruginosa PA14 (Yersinia subtype), E. coli UTI89 (Yersinia subtype), P. aeruginosa PA2192
(Escherichia subtype), Pseudomonas mendocina (Escherichia
subtype), and Pseudomonas stutzeri (Desulfovibrio subtype), are
shown in Fig. 4.
The Cas2 protein is coded for in some organisms by a gene
adjacent to the cas3 gene (Fig. 4A), and in a previous study,
Makarova and colleagues reported that Yersinia-subtype
CRISPR regions harbored in bacteria such as P. aeruginosa
PA14 and E. coli UTI89 have N-terminal Cas2-like domains
fused to the Cas3 protein (15, 23). However, while both P.
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FIG. 4. Conservation and domain architecture of Cas3 from multiple CRISPR region subtypes. (A) Columns (from left to right): bacterial
strain harboring CRISPR region, subtype of CRISPR regions (Y, Yersinia; E, Escherichia; D, Desulfovibrio), presence or absence of cas2 sequence
(NP, not present), and the cas3-encoded product. Black boxes denote HD domains, dark gray boxes represent conserved motifs of DEXD/H
domains, and white boxes show location of C-terminal helicase domains. (B to F) Conservation of Cas3 amino acid sequence around each
domain/motif. Stars represent residues that are 100% conserved, and black dots represent highly conserved sequences. Boxes are drawn around
key residues chosen for mutational analysis.

aeruginosa PA14 and E. coli UTI89 Yersinia-subtype Cas3 proteins were larger than the Cas3 proteins of other subtypes (Fig.
4A), protein sequence analysis provided no evidence of a fusion between Cas2 and Cas3 proteins (Fig. 4A; also see Fig.
S2A and B in the supplemental material). For example, none
of the residues previously published to be well conserved in
Cas2 (2) (see Fig. S2A, highlighted residues) are conserved in
the N termini of Yersinia-subtype Cas3 proteins. Further, only
one residue is 100% conserved between the previously studied
Cas2 homologs and the P. aeruginosa and E. coli Yersiniasubtype Cas3 proteins (see Fig. S2A), and while this residue
was previously implicated in Cas2 nuclease activity (2), its
conservation is likely a result of the CLUSTAL alignment
algorithm attempting to obtain at least some level of identity/
similarity between these clearly distinct protein sequences.
While it is formally possible that the N termini of Yersiniasubtype Cas3 proteins share a tertiary structure and/or biochemical activity with Cas2, we could not identify any DNA or
protein sequences indicative of the presence of a predicted
cas2 homolog in Yersinia-subtype CRISPR regions.
Predicted domain structure and conservation of Cas3. To
investigate the function of Cas3 in bacteriophage DMS3-mediated biofilm inhibition, we first inspected the protein sequence for conserved domains. The Cas3 proteins share three
conserved domains regardless of subtype in which they are
found: an N-terminal HD domain, a central DEXD domain
with multiple conserved motifs, and a C-terminal helicase domain (Fig. 4A).
HD domains are common yet poorly understood globular
domains that have been shown to participate in metal-dependent phosphohydrolysis of nucleotides such as cyclic di-GMP,

ppGpp, dGTP, and deoxyribonucleotides and have a highly
conserved HD motif (26).
In bacteria, DEXD/H proteins have been shown to play
roles in ribosome biogenesis, mRNA processing and decay,
and translation initiation (12). Nine motifs are found in canonical DEXD/H proteins, labeled Q, I, Ia, Ib, II, III, IV, V, and
VI (12). Our alignments show conserved motifs I, II, and to a
lesser degree III (Fig. 4C to E). Motif I (Walker A motif)
mediates interactions with ATP through hydrogen bonding of
the ␤ and ␥ phosphates of ATP with the conserved lysine
(K426 of Cas3) and an Mg2⫹ ion coordinated by the neighboring threonine (T427) (12). The initial aspartate (D576) and
glutamate (E577) of the DEXD/H sequence of motif II
(Walker B motif) are responsible for hydrolysis of ATP and
also coordinate the same Mg2⫹ as T427 (12). The terminal
aspartate (D579) interacts with the conserved serine (S607)
and alanine (A608) of motif III, which do not directly interact
with ATP but are believed to mediate ATP binding and helicase activities (12). Finally, the C-terminal helicase domain is
known to interact with the DEXD/H domain, aiding in both
substrate binding and ATP hydrolysis (20).
We utilized published structure/function and mutagenesis
studies of these domains (12, 26, 28), and our alignments, to
guide the analysis of Cas3’s role in phage-mediated biofilm
suppression and small crRNA production presented in the next
section.
Cas3 requires both its HD and DEXD/H domains for bacteriophage-mediated inhibition of biofilm formation but does
not impact small crRNA production. Deletion analysis of the
CRISPR region in P. aeruginosa PA14 showed that a ⌬cas3
mutant produces less mature crRNA than the wild type (Fig.
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FIG. 5. Requirement of the D124 and D576 residues of Cas3 for in vivo function. (A) Shown are the biofilm phenotypes of strains carrying the
WT Cas3, as well as the Cas3(D124A) and Cas3(D576A) mutants, in the presence of bacteriophage DMS3. A representative picture of the biofilm
formed by each strain is shown. An “L” following a genotype designation indicates a strain lysogenized with DMS3. (B) Quantification of biofilm
formed by each strain. The data shown are average values from eight independent wells. (C) Western analysis of WT and mutant Cas3 proteins
for each strain indicated, as detected by an anti-Cas3 antibody. (D) Northern blot analysis of small crRNA production of each strain. As in Fig.
2 and 3, the three spacers and two repeats closest to the cas1 gene of CRISPR2 of P. aeruginosa PA14 were used as the probe. Also shown at the
bottom of this panel is the 5S rRNA band for each of the corresponding RNA preparations used in the Northern blot analysis.

2C to E). However, we could not complement small crRNA
production in a ⌬cas3 mutant by expression of Cas3-His from
a plasmid (data not shown), and we could only partially rescue
the biofilm phenotype of a ⌬cas3 mutant by expression of
Cas3-His from a plasmid (Fig. 1D). Expression of the native
Cas3 protein from the same vector used to express Cas3-His
also did not fully complement the ⌬cas3 mutant. Together,
these observations suggested either that plasmid-encoded Cas3
was not functioning properly or that the ⌬cas3 mutation was
having polar impacts on downstream genes in the cas gene
cluster. As an alternative approach, we repaired the ⌬cas3
deletion mutation by placing the WT, untagged cas3 gene back
into its native locus. This chromosomal copy completely restored small crRNA production and biofilm inhibition to WT
levels in the presence of bacteriophage DMS3 (Fig. 5A, compare ⌬cas3 L versus ⌬cas3 L⫹WT).
We next made mutations in the HD (D124A) and DEXD/H
(D576A) domains of Cas3 to assess the roles of these domains
in CRISPR transcript processing and bacteriophage DMS3mediated biofilm inhibition. In contrast to the WT Cas3 protein, expression of the Cas3(D124A) and Cas3(D576A) mutant
proteins from their native chromosomal loci were both unable
to complement the biofilm phenotype (Fig. 5A and B, lanes 3
and 6) but, surprisingly, fully restored WT crRNA production
(Fig. 5D, lanes 3 and 6).
Complicating our interpretation of these studies was the fact
that Western blot analysis showed that WT Cas3 was more
abundant than both the D124A and D576A mutants (Fig. 5C),

indicating that the mutations impacted protein stability. To
address this issue, we overexpressed WT Cas3 and the mutant
proteins from a plasmid and did so in both cas3(D124A) and
cas3(D576A) chromosomal mutant backgrounds. Overexpression of the WT protein in the strains carrying the cas3(D124A)
and cas3(D576A) chromosomal mutations completely restored
biofilm inhibition and CRISPR processing to the WT phenotype (Fig. 5, compare lane 1 to lanes 4 and 7). In contrast,
high-level overexpression of the Cas3(D124A) and Cas3(D576A)
mutant proteins could not restore the WT biofilm-inhibited phenotype, despite the fact that these strains were producing small
crRNAs at levels equal to or greater than those of the WT (Fig.
5, compare lane 2 to lanes 5 and 8).
Taken together, these data suggest that Cas3 is indeed required for bacteriophage-mediated loss of biofilm formation
and that HD and DEXD/H are required for this phenotype,
but that neither domain plays a discernible role in the production and/or stability of small crRNAs.
CRISPR2 content required for bacteriophage DMS3-dependent biofilm inhibition. We next turned our attention to understanding the role of the Yersinia-subtype CRISPR2 in mediating bacteriophage-dependent loss of biofilm formation.
Current models suggest that CRISPR-mediated resistance to
bacteriophage and plasmids requires 100% identity between a
spacer sequence within the bacterial CRISPR and the corresponding portion of the plasmid or bacteriophage genome
(known as a protospacer) (23). This model, along with our
previous observation that P. aeruginosa PA14 CRISPR2 was
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FIG. 6. CRISPR2 spacer content required for bacteriophage-mediated biofilm inhibition. (A) The left column shows the name of the WT or
CRISPR2 mutant strain diagrammed in the center column. The CRISPR2 schematic representation depicts repeat sequences as black lines,
deleted sequence as dotted lines, WT spacers of PA14 CRISPR2 as gray boxes, P. aeruginosa strain 2192 CRISPR1 spacer 8 as black boxes, and
point mutations within spacer 1 as white boxes. Wild-type PA14 CRISPR2 spacer numbers are shown in intervals of 7 at the top of the center
column, allowing orientation of various spacer mutations. The right column provides a representative image of the biofilm phenotype of each
DMS3-infected WT and mutant strain. (B) Northern blot analysis demonstrating that the ⌬spacers1-2 (⌬sp. 1–2) mutant produces a level of small
crRNAs similar to that of the WT CRISPR2-complemented strain. The three spacers and two repeats closest to the cas1 gene of CRISPR2 of P.
aeruginosa PA14 were used as the probe. Also shown at the bottom of this panel is the 5S rRNA band for each of the corresponding RNA
preparations used in the Northern blot analysis. (C) Shown is the sequence of CRISPR2 spacer 1. The gray arrow shows the site of the mutation
caused by introduction of the SalI site, and the black arrows show the site of the mutation (left arrow) and base insertion (right arrow) caused by
introduction of the BamHI site. The black bar indicates the nucleotides comprising the restriction sites.

required for loss of biofilm formation (27), suggested that
CRISPR2 spacers (17 and 20) harboring identity to DMS3
were responsible for CRISPR-mediated biofilm inhibition.
We first established that we could complement the strain
lacking CRISPR2 by reintroducing the WT CRISPR2 region
back onto the chromosome in the ⌬CRISPR2 mutant (Fig. 6A,
compare rows 1 to 3). These data indicated that we had the
tools to also engineer variants of CRISPR2.
To determine the requirement for spacers 17 and 20 (i.e.,
those spacers with high sequence identity to regions of bacteriophage DMS3) in CRISPR-mediated biofilm inhibition, we
replaced each spacer with a sequence lacking high identity to
the DMS3 genome, namely, spacer 8 from Yersinia-subtype
CRISPR1 of P. aeruginosa strain PA2192. The PA2192 spacer
shared only 8 nucleotide residues at identical locations with
that of CRISPR2 spacer 17 and shared 14 residues with spacer
20. These CRISPR mutants with altered spacers 17 or 20
retained the ability to disrupt biofilm formation in the presence
of DMS3, indicating that neither of these sequences is required
for this phenotype (Fig. 6A).
We next deleted CRISPR2 spacers 7 to 21 (⌬spacers7-21),
thereby removing spacers 17 and 20 simultaneously, and replaced this region with the single P. aeruginosa PA2192 spacer

8. We found that none of these spacers were required for
DMS3-dependent biofilm inhibition (Fig. 6A). It is important
to note that spacer 8 of P. aeruginosa PA2192 is introduced
here and in all the deletion constructs below to streamline the
screening of candidate CRISPR mutants, as outlined in Materials and Methods.
We subsequently removed spacers 2 to 21 (⌬spacers2-21),
and the strain still retained DMS3-mediated biofilm inhibition,
indicating that only CRISPR2 spacer 1 was necessary for this
phenotype (Fig. 6A). Deletion of all the spacers and introduction of just spacer 8 of P. aeruginosa PA2192 (⌬all spacers) did
restore biofilm formation, indicating that spacer 1 was critical
for DMS3-mediated biofilm inhibition. Unfortunately, multiple PCR primers failed to amplify the correct fragments required to create a CRISPR2 spacer 1 in-frame replacement
construct and the corresponding mutant. However, we were
able to replace both spacers 1 and 2 with spacer 8 of P. aeruginosa PA2192, and this mutant lacking only spacers 1 and 2
(⌬spacers1-2) behaved like a CRISPR2 deletion; that is, this
mutation restored the ability of P. aeruginosa PA14 to form a
biofilm when lysogenized by bacteriophage DMS3 (Fig. 6A). It
is also important to note that in nonlysogens, none of these
CRISPR2 mutants displayed a biofilm phenotype (data not
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shown). Together, these data indicate that spacer 1 is critical
for the CRISPR-dependent loss of biofilm formation in DMS3
lysogens.
To make certain that the biofilm-positive ⌬spacers1-2 mutant was still able to transcribe and process the remaining
CRISPR2 spacers, we analyzed small crRNA production.
Northern blot analysis of ⌬CRISPR2, ⌬CRISPR2⫹CRISPR2,
and ⌬CRISPR2⫹⌬spacers1-2 mutants (Fig. 6B) shows that
while the ⌬CRISPR2⫹⌬spacers1-2 mutant produces crRNA
at a level similar to that of the WT complement, it cannot
inhibit biofilm formation.
Although we were unable to delete spacer 1 (see above), we
were able to create point mutations within the spacer sequence
by introducing unique restriction sites. We introduced a
BamHI restriction enzyme site into spacer 1, resulting in a 2-bp
mutation near the center of the spacer (adding one nucleotide
to the spacer length), while the addition of a SalI site altered
only a single nucleotide near the end of the spacer (the location of point mutations are denoted by arrows in Fig. 6C).
Neither the SalI nor BamHI point mutations were able to
inhibit biofilm formation in the presence of bacteriophage
DMS3, indicating that spacer 1 requires these nucleotides for
function (Fig. 6, compare rows 1, 2, 10, and 11).
Together, these analyses demonstrate that the CRISPR-mediated interaction between P. aeruginosa PA14 and bacteriophage DMS3 is dependent only on CRISPR2 spacer 1, and
furthermore, that there are sequence determinants of spacer 1
important for its function.
A role of DMS3 gene 42 in DMS3-mediated biofilm inhibition. Comparison of PA14 CRISPR2 spacer 1 against the
NCBI database by using BLASTN identified no sequences with
100% identity, thus providing no obvious putative targets for
this spacer (i.e., protospacers). The bacteriophage DMS3 sequence with the highest overall identity to spacer 1 was a
portion of DMS3-42 (see Table S2 in the supplemental material), which was identical at 27 of 32 nucleotides (Fig. 7A). To
verify that bacteriophage DMS3 had not been mutated in this
region, we resequenced DMS3-42 in the lysogen and found no
alteration from the previously reported DMS3 genome sequence (27). These data indicated that a non-identity-mediated interaction between spacer 1 and DMS3-42 might be responsible for the impact on biofilm formation.
We employed several approaches to address whether nonidentity-mediated interaction between spacer 1 and DMS3-42
might be responsible for the inhibition of biofilm formation.
First, we deleted the DMS3-42 gene from the lysogen and
observed restoration of biofilm formation; that is, the lysogen
lacking the DMS3-42 gene showed a biofilm phenotype identical to that of a strain carrying a deletion of the CRISPR2
region (Fig. 7B), confirming a role for the DMS3-42 gene in
DMS3-mediated biofilm inhibition. Of note is that the deletion
of the DMS3-42 gene resulted in a lysogen that produced no
detectable phage particles, as determined by PFU assay, indicating that the DMS3-42 gene product is critical for the DMS3
phage life cycle.
Second, we exploited the mutation in spacer 1 of CRISPR2
caused by introduction of the SalI restriction site (Fig. 6A and
C), which resulted in a transversion of the C7 position of this
spacer to a guanine nucleotide (Fig. 7A, asterisk). To determine whether a compensatory mutation within the DMS3-42
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FIG. 7. DMS3-42 is targeted by CRISPR2 spacer 1. (A) Alignment
of the CRISPR2 spacer 1 sequence with the complementary portion of
the DMS3-42 sequence. The DMS3-42 numbering is measured from
the putative translational start site. The asterisk denotes the location of
spacer 1 C7G point mutation. (B) The biofilm phenotypes of WT
nonlysogen, as well as the DMS3 infected-WT, ⌬CRISPR2 and
⌬DMS3-42 mutants. A representative image of the biofilm formed by
each strain is shown above the quantification of results for 8 independent wells. An “L” following a strain designation indicates a strain
lysogenized with DMS3. (C) Representative images of the biofilm
phenotypes of the WT and the spacer 1 (sp. 1) C7G point mutant
(harboring a SalI restriction site) in the absence of bacteriophage.
(D) Biofilm phenotypes of the WT and the spacer 1(C7G) mutant
lysogenized by bacteriophage DMS3. (E) Biofilm phenotypes of the
WT and spacer 1(C7G) mutant bacteria lysogenized by DMS342(C238G) mutant bacteriophage DMS3.

gene could restore the biofilm inhibitory phenotype to a strain
carrying the spacer 1(C7G) mutation, we constructed the corresponding C238G point mutation in the DMS3-42 gene and
introduced this mutation onto the chromosome of the
⌬DMS3-42 strain. The DMS3-42(C238G) mutation was able to
restore biofilm inhibition in the presence of the spacer 1(C7G)
mutation but not in the presence of the WT spacer 1 sequence
(Fig. 7C, D, and E).
It should be noted that the DMS3-42(C238G) mutation is
predicted to introduce an L80V mutation in the DMS3-42
protein sequence. However, this mutation still retained the
ability to produce approximately WT levels of bacteriophage
particles as measured by plaque assay (data not shown), indicating that this mutation did not eliminate the function of the
DMS3-42 protein.
Previously, we reported that both Pseudomonas aeruginosa
PA14 and other clinical isolates with functional CRISPR regions did not mediate resistance to bacteriophage harboring
sequences 100% identical to spacers within their CRISPRs (5).
An efficiency-of-plating (EOP) assay was utilized to determine
if WT and spacer 1(C7G) mutant CRISPR regions were
equally susceptible to WT and DMS3-42(C238G) mutant bacteriophages, respectively. Interestingly, WT and spacer 1(C7G)
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FIG. 8. Non-identity-mediated targeting of CRISPR2 spacer 1 to DMS3-42. (A) Shown is a diagram of CRISPR2 spacer 1 (top) and selected
regions of the DMS3-42 gene (bottom). The putative ATG translational start site of DMS3-42 is shown to the left, while the two regions of
complementarity between CRISPR2 spacer 1 and DMS3-42 are shown to the right (with the flanking gene sequence denoted by a thick dashed
line). CRISPR2 spacer 1 sequence is boxed and aligned with the two complementary regions of DMS3-42. Light gray, underlined DMS3-42
nucleotides are not identical between CRISPR2 spacer 1 and DMS3-42. The two CRISPR2 spacer 1 sequences have been numbered for ease of
analysis, and an asterisk placed at the site of the C7G point mutation. The locations of point mutations made in the DMS3-42 gene are shown above
the DMS3-42 nucleotide sequence. The putative amino acid sequence of the regions of complementarity is shown below DMS3-42 nucleotide
sequence. (B) DMS3-42 point mutations that retain or abolish CRISPR2 spacer 1-mediated biofilm inhibition. Black arrows signify point mutations
that restored biofilm formation in the presence of DMS3, while white arrows denote those that had no detectable effect on biofilm phenotype. The
C256/C258 double mutant is boxed. (C) Representative image of the biofilm phenotype of each indicated strain from the quantification of results
for at least 7 biofilm wells. White bars signify strains that retain the phenotype of the WT lysogen, that is, no biofilm formation, while black bars
denote strains that show restored biofilm formation.

mutant strains were equally susceptible to both WT and
DMS3-42(C238G) mutant bacteriophages, with measured
EOPs of 1.1 ⫾ 0.02 and 1.7 ⫾ 0.89, respectively, confirming
that the Yersinia-subtype CRISPR region plays no detectable
role in bacteriophage resistance.
Taken together, these data indicate that the interaction between spacer 1 and a nonidentical region of the DMS3-42
sequence is required for phage DMS3-mediated biofilm inhibition but not for bacteriophage resistance.
The DMS3-42 protein is not required for phage-mediated
biofilm inhibition. The requirement for DMS3-42 in DMS3mediated biofilm inhibition raised the question of whether the
DMS3-42 protein has a role in this CRISPR-dependent phenotype. To assess the contribution of the DMS3-42 protein to
biofilm inhibition, we mutated the predicted DMS3-42 translational start site by introducing a T2G point mutation into the
chromosomal copy of the DMS3-42 gene (Fig. 8A and B). This
DMS3-42(T2G) mutant, like the ⌬DMS3-42 deletion mutant,
does not produce detectable levels of bacteriophage as measured by the plaque assay (not shown), corroborating that the
DMS3-42 protein is required for the DMS3 life cycle and that
the T2G mutation likely abrogated production of this protein.
However, the DMS3-42(T2G) lysogen was still unable to form
a biofilm, in contrast to the ⌬DMS3-42 lysogen, which shows a
WT level of biofilm formation (Fig. 8C, compare column 5 to
columns 1, 2, and 3). Together, these data indicate that while

DMS3-42 protein is required for the production of viable
DMS3 phage particles, this protein is not required for phagemediated biofilm inhibition.
Nucleotide requirements of the DMS3-42 target sequence.
The finding that CRISPR2 spacer 1 interacts with gene
DMS3-42 indicates that 100% identity between spacer and
target is not required; however, the observation that the
CRISPR2 spacer 1(C7G) mutation is sufficient to completely
abolish biofilm inhibition is consistent with a requirement for
complementarity at some nucleotides. To better understand
the sequence required for spacer 1 targeting of DMS3-42,
multiple point mutations were introduced in the two regions of
complementarity between spacer 1 and DMS3-42. The first
region of complementarity is identical to CRISPR2 spacer 1 at
27 of 32 nucleotides, while the second region shares 19 of 32
bases (Fig. 8A). Care was taken to introduce point mutations
that would not affect the DMS3-42 protein sequence, when
possible, and so maintain DMS3-42 protein function.
Mutations were created in at least one nucleotide of every
codon within the first complementarity region, while two selected mutations were made within the second region of lower
complementarity (Fig. 8A). Although we attempted to make
single-base-pair mutations that maintained the DMS3-42 protein sequence, four point mutations resulted in amino acid
substitutions (G235T3A79S, C238G3L80V, T254C3L85P,
and A262T3M88L). Only the DMS3-42(T254C3L85P) mu-

VOL. 193, 2011

CRISPR-BACTERIOPHAGE INTERACTIONS

tant was unable to produce bacteriophage particles and therefore likely had a marked negative effect on DMS3-42 protein
function (data not shown). The C256A C258A double mutation was created to test the requirement of C256 (C258 already
differs from CRISPR2 spacer 1) while retaining the WT amino
acid sequence of the DMS3-42 protein.
The ability of each DMS3-42 mutant to form a biofilm was
assayed and quantified (Fig. 8C). The C234T, C246T, C252T,
C663T, and G681T mutations all retained the ability to inhibit
biofilm formation, indicating that they are not required for
CRISPR2 spacer 1 interaction with DMS3-42 (Fig. 8B and C,
white arrows and bars). However, the G235T, C238T, C238G,
C243T, C249T, T254C, G261T, and A262T mutants and the
C256A C258A double mutant were all unable to suppress
biofilm formation, implicating them in CRISPR2 spacer 1 targeting (Fig. 8B and C, black arrows and bars). Finally, the
observation that C238T and C238G mutants have different
abilities to suppress biofilm formation (Fig. 8C) is consistent
with some nucleotide substitutions being tolerated more than
others at certain positions.
DISCUSSION
Our work has shown that the Yersinia-subtype CRISPR
region of P. aeruginosa PA14 plays no detectable role in viral
immunity but instead is required for bacteriophage DMS3dependent inhibition of biofilm formation by P. aeruginosa.
This finding is in contrast to the work reported for other
CRISPR subtypes (1, 3). Because of the distinct function
proposed for the Yersinia-subtype CRISPR region, we
sought to identify the components of this specific CRISPR
system that are required to mediate DMS3-dependent biofilm inhibition. While our findings in some cases confirmed
previous reports from other groups, this work also provides
new insight into which components of the Yersinia-subtype
CRISPR region are required for bacteriophage DMS3-mediated biofilm inhibition.
We are the first to demonstrate the in vivo requirement
for both csy4 and csy2 in the production and/or stability of
small crRNA. Decreased crRNA levels were also observed
in the csy1 and csy3 mutant backgrounds, indicating that
their protein products aid in crRNA production or stability.
Others have speculated that the Csy proteins form a complex involved in crRNA processing (23); however, the similar stabilities of tagged Csy4 in the csy1-3 mutants indicate
roles for these Csy proteins other than stabilizing Csy4 in
vivo. An important caveat of this conclusion is that, to assess
its stability, Csy4 was expressed from a plasmid rather than
its native locus; thus, it is still formally possible that Csy1-3
may impact the stability of the Csy4 protein in the native
context.
We would like to stress that this study does not contradict
previous work demonstrating that Csy4 is necessary and
sufficient to process CRISPR transcript in vitro (11). In their
study, Haurwitz and colleagues showed that coexpression of
Csy4 and its cognate CRISPR transcript in E. coli results in
robust crRNA production (11). Taken together, these data
suggest that no other Cas proteins are required for crRNA
production. The work here indicates that a mutation in the
csy2 gene results in no detectable crRNA in vivo, while
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mutating the csy1 or csy3 gene results in a marked decrease
in crRNA levels. It is possible that in its native context in P.
aeruginosa, Csy4 does require accessory factors to produce
crRNA, or alternatively, that the Csy1-3 proteins are required to stabilize the crRNA produced by Csy4. Going
forward, the tools developed here can help elucidate the in
vivo function of each of the Cas proteins in small crRNA
production.
Determining the function of the few conserved cas gene
products found in multiple CRISPR region subtypes is key
to understanding shared CRISPR region mechanisms. The
core cas gene cas3 is found in 6 of 8 CRISPR region subtypes (23), and has been shown recently to be a singlestranded DNA nuclease and ATP-dependent helicase (22).
Our studies indicate that Cas3 requires both its HD and
DEXD/H domains to function in biofilm inhibition, and
mutations similar to those analyzed here (Fig. 4 and 5) were
reported to disrupt the nuclease and helicase activities of
Cas3 in vitro (22). Thus, our in vivo studies corroborate the
conclusions drawn from the published Cas3 in vitro studies
(22). Furthermore, the mutants with point mutations in the
Cas3 HD and DEXD/H domains are the only biofilm-positive cas mutants we found to have crRNA production equivalent to that of the WT strain, indicating that in the context
of the bacteriophage-CRISPR interaction in vivo, the Cas3
HD and DEXD/H domains function in a process other that
of small crRNA production, and we favor the model that
Cas3 maybe an effector protein.
Considerable effort was also taken to identify the previously proposed Cas2-Cas3 fusion protein; however, no evidence was found supporting a Cas2 protein encoded within
the Yersinia-subtype CRISPR region. This analysis indicates
that Cas2 is not found in all CRISPR region subtypes, as has
been previously reported (15, 23).
Broadly accepted CRISPR doctrine states that CRISPR/
cas interactions require 100% identity between the spacer
and target (protospacer). Our comprehensive deletion analysis of CRISPR2 clearly demonstrates that while CRISPR2
spacer 20 has 100% identity to bacteriophage DMS3, this
spacer plays no role in the CRISPR-mediated biofilm phenotype. Unexpectedly, our data indicate that spacer 1 of
CRISPR2, which is not 100% identical to any sequence in
the GenBank sequence database, mediates the bacteriophage DMS3-dependent inhibition of biofilm formation. We
also demonstrate that CRISPR2 spacer 1 impacts biofilm
formation through interaction with the DMS3-42 gene and
that this interaction does not require DMS3-42 protein production. Interestingly, DMS3-42 harbors two regions of
complementarity to CRISPR2 spacer 1; however, only one
seems to be required for the CRISPR2 spacer 1-mediated
loss of biofilm formation. If the preexisting mismatches between spacer 1 and the DMS3-42 sequence and the thorough
mutational analysis presented here are combined, we have
analyzed half of the nucleotides within the region of greatest
complementarity between CRISPR2 spacer 1 and DMS3-42,
thereby identifying 8 nucleotides required for the interaction between CRISPR2 spacer 1 and DMS3-42. Together,
these data challenge current CRISPR models invoking the
need for 100% identity between spacers and targets. Our
findings are consistent with a recent study published while
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this paper was under review outlining an Escherichia-subtype CRISPR region interacting with a plasmid that lacked
100% identity to any spacer sequences (18).
There are several models that could explain how the
spacer 1 interaction with DMS3-42 might impact the DMS3
lysogen. The spacers encoded by the Mycobacteria- and Neisseria-subtype CRISPRs have been postulated to direct a
DNA nuclease against invading foreign DNA, resulting in
cleavage of the target DNA (9, 16). We do not favor such a
DNA-targeting model at this time, because CRISPR-mediated cleavage of the lysogenized DMS3 would negatively
impact viable counts of the lysogen and phage titers and/or
alter resistance to DMS3 infection—we have not observed
any of these phenotypes in our studies (5, 27). Alternatively,
the Yersinia-subtype CRISPR region may be modulating
production and/or stability of transcripts produced by the
lysogen. In the case of DMS3-42, which is located within a
predicted ⬃17-kb operon including 20 other putative genes,
any impact on message stability mediated by spacer 1 has the
potential to positively or negatively impact the expression of
one or more proteins encoded in this region. Our ongoing
studies aim to understand the mechanism by which spacer
1-mediated effects impede biofilm formation.
The seminal work of Barrangou et al. (1) and Deveau et
al. (7) in Streptococcus thermophilus concluded that spacermediated resistance of S. thermophilus to bacteriophages
858 and 2972 requires 100% identity between the spacer
and its bacteriophage target (7). However, the analysis that
produced this conclusion included only bacteriophage mutants selected to become resistant to the spacer sequence
and excluded all sequence changes that do not alter resistance. Our comprehensive mutagenesis studies here show
that a single-point mutation may or may not disrupt spacermediated processes, and we suggest that the model invoking
the requirement for a 100% match between spacer and
target must be revisited and vetted more thoroughly.
It is widely accepted that CRISPR can be transcribed into
a large transcript and processed into small crRNAs by Cas
proteins. However, it is becoming increasingly clear that
CRISPR regions of different subtypes may utilize these
crRNAs differently. This observation is perhaps less striking
when it is considered that only the cas1 gene is found in all
CRISPR region subtypes. Additionally, experimental evidence has shown that the Staphylococcus epidermidis and S.
thermophilus CRISPR regions (Mycobacteria and Neisseria
subtypes, respectively) target DNA, while that of Pyrococcus
furiosus (Thermotoga subtype) targets RNA in vitro (9, 10,
16), indicating the possibility for different output activities
for these CRISPR subtypes. In this study, we demonstrate
CRISPR-mediated interaction with a lysogenized bacteriophage, which could have a profound implication for a number of environmental and pathogenic bacteria that have
their phenotypes modulated by integrated bacteriophages.
Given that the DMS3 phage studied here shares high sequence similarity to Mu phage and replicates via a transposition-based mechanism, we would not be surprised if the
Yersinia-subtype CRISPR might also target transposons. Together, these findings lead us to assert that each CRISPR
region should not be assumed to have a role in resistance to
phage infection until such a conclusion is experimentally
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validated. It is critical that novel CRISPR/cas interactions
not be dismissed out of hand as nonfunctional or degenerate
simply because they do not fit previous models for other
subtypes. We propose that a CRISPR region should be
considered functional if the region is demonstrated experimentally to be transcribed and processed into small
crRNAs. Finally, this work indicates that some CRISPR/cas
interactions may require considerably less than 100% identity between a CRISPR spacer and its “target,” forcing us to
reevaluate the use of bioinformatics as the sole mechanism
of determining spacer-targeted interactions.
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